Video
Dr. Concin on the Rationale for the LIO-1 Trial in Advanced Gynecologic Malignancies
Author(s):
Nicole Concin, MD, discusses the rationale for the phase 1/2 LIO-1 trial in advanced gynecologic malignancies.
Nicole Concin, MD, professor, experimental gynecology, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, discusses the rationale for the phase 1/2 LIO-1 trial in advanced gynecologic malignancies.
The phase 2 portion of the LIO-1 trial will evaluate the safety and efficacy of lucitanib, an investigational and potent TKI that inhibits VEGFR 1-3, PDGFRα/β, and FGFR 1-3, in combination with nivolumab (Opdivo) in patients with advanced gynecologic solid tumors, says Concin.
Notably, the rationale to combine angiogenesis inhibitors with immunotherapy is based on preclinical data that demonstrated increased efficacy with this approach, Concin concludes.
